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Abstract 
Background: Mesenchymal stem cells (MSCs) are regarded as a promising cell-based therapeutic tool for tendon 
repair. This study aimed to compare the different tenogenic differentiation capacities of the three types of MSCs in the 
presence of bone morphogenic protein 12 (BMP-12).
Methods: MSCs were isolated from rat bone marrow (BM), inguinal adipose tissue (AD), and synovium (SM) from the 
knee joint. MSCs were characterized by morphology, proliferation, trilineage differentiation, and surface marker analy-
sis. Tenogenic differentiation potential was initially assessed using real-time polymerase chain reaction, Western blot, 
and enzyme-linked immunosorbent assay in vitro. Histological assessments were also performed after subcutaneous 
implantation of BMP-12 recombinant adenovirus-infected MSCs in nude mice in vivo.
Results: The three types of MSCs exhibited similar fibroblast-like morphology and surface markers but different dif-
ferentiation potentials toward adipogenic, osteogenic, and chondrogenic lineage fates. Bone marrow-derived MSCs 
(BM-MSCs) showed the most superior in vitro tenogenic differentiation capacity, followed by synovial membrane-
derived MSCs (SM-MSCs) and then adipose-derived MSCs (AD-MSCs). After implantation, all three types of MSC 
masses infected with BMP-12 recombinant adenovirus emerged in the form of fiber-like matrix, especially in 6-week 
specimens, compared with the control MSCs in vivo. BM-MSCs and SM-MSCs revealed more intense staining for 
collagen type I (Col I) compared with AD-MSCs. Differences were not observed between BM-MSCs and SM-MSCs. 
However, SM-MSCs demonstrated higher proliferation capacity than BM-MSCs.
Conclusion: BM-MSCs exhibited the most superior tenogenic differentiation capacity, followed by SM-MSCs. By  
contrast, AD-MSCs demonstrated the inferior capacity among the three types of MSCs in the presence of BMP-12 
both in vivo and in vitro.
© 2015 Dai et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided 
you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate 
if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Tendon injuries are common diseases in the musculo-
skeletal system. At least 300,000 people undergo surgi-
cal tendon repairs each year in the United States [1]. 
Unfortunately, healing of the injured tendon is poor 
because of its limited regenerative potential [2]. Moreover, 
this injury has a long recovery time, ranging from months 
to years. Healed tendons do not regain their initial prop-
erties, and significant dysfunction may ensue [3, 4]. Thus, 
improving the efficiency of tendon repair is imperative.
Several cytokines, including bone morphogenetic pro-
teins (BMPs), transforming growth factor-beta (TGF-β), 
insulin-like growth factor (IGF), vascular endothelial 
growth factor (VEGF), and fibroblast growth factor 
(FGF) [5–9], can enhance tendon repair. However, not 
all aforementioned cytokines can promote tenogenic 
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differentiation in cell-based therapeutic methods. Among 
these cytokines, bone morphogenic protein (BMP-12), 
also called growth and differentiation factor 7, has shown 
the most superior capacity to promote tendon repair and 
tendon-like tissue formation both in vivo and in vitro [8, 
10–12]. BMP-12 can also promote tenogenic differentia-
tion of mesenchymal stem cells (MSCs) and even muscle 
cells [13]. Overall, BMP-12 has remarkable therapeutic 
potential for tendon repair.
MSCs are also regarded as a promising cell-based ther-
apeutic tool for tendon repair [14–16]. These cells can 
rapidly proliferate in vitro and can easily be isolated from 
various tissues, including bone marrow aspirates [17], adi-
pose tissues [18], muscles [19], and synovium [20]. Moreo-
ver, MSCs are multipotent and can thus differentiate into 
several tissues, including bone, cartilage, adipose, and other 
tissues, under appropriate culture conditions. The capacity 
of MSCs to differentiate into tenocytes and form tendon 
tissue has been demonstrated [12, 21–23]. However, MSCs 
from different tissues are different in terms of proliferation, 
isolation, and especially differentiation capacity.
An assessment to determine the type of MSCs that 
exhibits the most superior differentiation capacity toward 
tenocyte should be conducted to screen the optimum 
cell source for tenogenic differentiation. Therefore, in 
this study, we characterized the tenogenic differentiation 
capacities of rat bone marrow-derived MSCs (BM-MSCs), 
adipose tissue-derived MSCs (AD-MSCs), and syno-
vial membrane-derived MSCs (SM-MSCs) infected with 
BMP-12 recombinant adenovirus (Ad-BMP-12) in  vitro. 
We also tested whether the tenocyte-like phenotype is 
sustained following implantation in nude mice in vivo.
Methods
Isolation and culture of MSCs
All MSCs were isolated from Sprague–Dawley rats (100–
120 g, n = 5) in this experiment. BM-MSCs were collected 
from the bone marrow by flushing the femur and tibia 
with medium, and single-cell suspensions were prepared 
by repetitively pipetting BM-MSCs through 18-gauge 
needles as described [20]. After centrifugation, cell pel-
lets were suspended in the growth medium. AD-MSCs 
were isolated from the inguinal adipose tissue of the rats 
as previously described [24]. The tissue was minced and 
digested in phosphate-buffered saline (PBS) containing 
0.1% type I collagenase (Sigma-Aldrich, St. Louis, Mo, 
USA) for 60 min at 37°C with vigorous shaking. After cen-
trifugation, the top lipid layers were removed, and the cells 
were suspended in the growth medium. SM-MSCs were 
isolated from the synovium tissue, which comes from the 
inner side of the medial joint capsule using a pituitary 
rongeur under arthroscopic observation. The synovium 
tissue was cut into small pieces and was then digested 
with 0.1% type I collagenase (Sigma) for 60  min at 37°C 
with vigorous shaking. Cells were then expanded in mon-
olayers in the growth medium according to the described 
methods [25]. Dulbecco’s modified eagle medium 
(DMEM, Invitrogen, Carlsbad, CA), supplemented with 
10% fetal bovine serum (FBS, Invitrogen), 100 U/mL peni-
cillin, and 100 mg/mL streptomycin (1% P/S, Invitrogen), 
was used as growth medium. The medium was replaced 
every 2–3 days. The cells used in subsequent experiments 
were at passage 3 and were CD90+, CD105+, CD73+/
CD45− cells.
Ad‑BMP‑12 infection
The adenoviral vector Ad-BMP-12 was constructed as 
we previously reported [26]. A recombinant adenoviral 
vector expressing green fluorescent protein (GFP) alone 
was used as a control vector (Ad-GFP). The three types 
of passage 3 MSCs were cultured in the growth medium 
to approximately 90% confluence, and Ad-BMP-12 was 
added according to the multiplicity of infection (MOI). 
The MSCs infected with Ad-GFP were used as control.
Proliferation assay
The three types of MSCs were seeded in 96-well plates 
at a density of 5  ×  103 cells/well and cultured in the 
aforementioned growth medium at 37°C under 5% CO2 
atmosphere for 1, 2, 3, 4, 5, and 6  days. Cell prolifera-
tion activity was measured using Cell Counting Kit-8 
(CCK-8, Dojindo, Kumamoto, Japan), in which 10  μL 
of the CCK-8 assay solution was added to each well and 
incubated for 4 h at 37°C. The absorbance was measured 
using a microplate reader (Bio-Rad, Munich, Germany) 
at a wavelength of 450 nm.
Chondrogenic, osteogenic and adipogenic differentiation
A pellet culture system was used for chondrogenic differ-
entiation. Approximately 2.5 × 105 MSCs were placed in 
a 15 mL tube and pelleted under centrifugation at 500 g 
for 10 min. The pellet was cultured in 500 μL of serum-
free chondrogenic induction medium (RASMX-90041, 
Cyagen). The medium was replaced every 3 days for up 
to 21  days. For osteogenic differentiation, 3  ×  103/cm2 
cells were cultured in the osteogenic induction medium 
(RASMX-90021, Cyagen) for 2–3  weeks according to 
the manufacturer’s instructions. For adipogenic differ-
entiation, 2 × 104/cm2 cells were cultured in the adipo-
genic induction medium and the maintenance medium 
(RASMD-90021, Cyagen), following manufacturer’s 
instruction. Cells in the control group were maintained 
only in the maintenance medium according to the same 
schedule.
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Flow cytometric analysis
For surface marker analysis, 1 × 106 of each of the three 
types of MSCs were washed, incubated with fluorescein 
isothiocyanate (FITC)-conjugated CD105, CD73, CD45, 
and CD90 antibodies (Abcam, Cambridge, UK) in 1% 
FBS/PBS for 1  h. After three washes with 1% FBS/PBS, 
the cells were resuspended in 500 μL of PBS. For nega-
tive controls, FITC-conjugated nonspecific IgG fractions 
(Abcam) were substituted for the primary antibodies. 
All the above procedures were performed in the dark at 
4°C. The expression profiles of CD105, CD73, CD45, and 
CD90 on the three types of MSCs were examined using a 
flow cytometer (B&D, San Jose, CA, USA) and analyzed 
with Cell-Quest 3.1 software (B&D).
For the assessment of Ad-BMP-12 infection efficiency, 
the three types of MSCs were first initially subjected to 
Ad-BMP-12 infection for 1 and 3 days at different MOIs. 
The infection efficiency was then evaluated using flow 
cytometer (B&D) and analyzed with Cell-Quest 3.1 soft-
ware (B&D). The MSCs without Ad-BMP-12 infection 
were used as control.
Quantitative RT‑PCR
Total RNA was extracted from Ad-BMP-12 infected 
MSCs using TRIzol reagent (Invitrogen). Isolated RNA 
was reverse-transcribed with a commercial kit (Pro-
mega, Madison, WI, USA), and real-time RT-PCR 
analysis was performed using the Step-One plus Sys-
tem (Applied Biosystems, Foster City, CA, USA) with 
SYBR Green Select Master Mix (Applied Biosystems). 
The conditions of real-time RT-PCR were as follows: 
50°C for 2  min, 95°C for 2  min, followed by 40 cycles of 
95°C for 15 s and 60°C for 30 s. A dissociation stage was 
added at the end of the amplification procedure. There 
was no nonspecific amplification determined by the dis-
solved curve. The PCR primers are as follows: peroxisome 
proliferator-activated receptor γ (PPARγ): forward: 5′ 
TGGAGCCTAAGTTTGAGTTTGC 3′, reverse: 5′-TGAC 
AATCTGCCTGAGGTCTG-3′; osteocalcin (OCN): for-
ward: 5′-GCACCACCGTTTAGGGCAT-3′, reverse: 
5′-AGAGAGAGGGAACAGGGAG-3′; collagen type II 
(Col II): forward: 5′-CACCGCTAACGTCCAGATGAC-3′, 
reverse: 5′-GGAAGGCGTGAGGTCTTCTGT-3′; ten-
omodulin (Tnmd): forward: 5′-GGGATTGACCAGAAT 
GAGCAA-3′, reverse: 5′-GGTGCGGCGGGTCTTC-3′; 
tenascin C (Tnc): forward: 5′-CAGAAGCTGAACCGG 
AAGTTG-3′, reverse: 5′-GGCTGTTGTTGCTAG 
GCACT-3′; scleraxis (SCX): forward: 5′-TGGCC 
TCCAGCTACATTTCT-3′, reverse: 5′-TGTCACGGTC 
TTTGCTCAAC-3′; collagen type I (Col I): forward: 
5′-TTTCCACATGCTTTATTCCAGC-3′, reverse: 5′-TCC 
TGGGCCTATCTGATGATCT-3′; GAPDH: for-
ward: 5′-GCAAGTTCAACGGCACAG-3′, reverse: 
5′-GCCAGTAGACTCCACGACA-3′. The expression of 
the above genes relative to GAPDH were determined using 
the 2−ΔΔCT method [27].
Enzyme‑linked immunosorbent assay
The concentration of collagen type I (Col I) secreted 
into the culture supernatants by MSCs after Ad-BMP-12 
infection was measured using a rat Col I enzyme-linked 
immunosorbent assay (ELISA) kit (Chondrex, Redmond, 
WA, USA) according to the manufacturer’s instructions. 
The absorbance was measured using a microplate reader 
(Bio-Rad) at a wavelength of 450  nm, and the results 
were compared with a standard curve constructed from a 
standard Col I solution. We confirmed that these kits did 
not cross-react with the medium itself, regardless of the 
presence or absence of FBS.
Protein isolation and Western blotting
Protein was extracted using lysis buffer (50  mM Tris–
HCl, pH 7.4, 150 mM NaCl, 1% NP- 40, and 0.1% sodium 
dodecyl sulfate), and the concentration was measured 
using the BCA protein assay kit (Pierce, Rockford, IL, 
USA) using bovine serum albumin as the standard. Pro-
teins were run on SDS-PAGE gels (12%) and electro-
transferred to nitro-cellulose membrane at 4°C for 2  h. 
The blots were probed with anti-SCX (Abcam), anti-
Tnmd (Santa Cruz, Santa Cruz, CA, USA) and anti-Tnc 
(Santa Cruz) at 1:1,000 dilutions overnight at 4°C, fol-
lowed by incubation with horseradish peroxidase-conju-
gated secondary antibody (Santa Cruz, 1:1,000 dilutions) 
at room temperature for 1 h. Proteins were detected by 
chemiluminescence according to the manufacturer’s rec-
ommendations (ECL, Millipore, Bedford, MA, USA). 
Beta-tublin (Santa Cruz) was used as an internal control.
In vivo implantation and histological analysis
All animal experimental protocols were approved by the 
Animal Care and Use Committee of Peking University and 
conformed to the National Institutes of Health guidelines 
(LA 2010–066). MSCs infected with Ad-BMP-12 or Ad-GFP 
(4 × 106) were injected subcutaneously into the right axillary 
region of nude mice (n = 8). MSCs infected with Ad-GFP 
were used as control. After 3 and 6 weeks, the mice were sac-
rificed with ether anesthesia, samples were measured with 
weight and area, and then were fixed in 4% paraformalde-
hyde (pH 7.4) for 48 h at 4°C. For standard histological evalu-
ation, the sections were stained with hematoxylin and eosin 
(H&E). For immunohistochemical staining, the sections 
were incubated overnight at 4°C with anti-Col I, followed by 
a 30 min incubation with a secondary antibody conjugated 
with horseradish peroxidase (1:1,000, Santa Cruz) in 0.1% 
PBS. Col I was quantified using Image-Pro Plus 6.0 software 
(Media Cybernetics, Silver Spring, MD, USA).
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Statistical analysis
For statistical analysis, the statistical significance of the 
differences between groups was calculated using analysis 
of variance (ANOVA). The results from the same group 
were evaluated using Student’s t test. P values <0.05 were 
considered statistically significant. All data are presented 
as mean ± SD.
Results
Characteristics of MSCs from bone marrow, adipose tissue, 
and synovium
Isolated MSCs from the three types of tissues showed a 
fibroblast-like morphology (Figure 1a–c). MSCs (5 × 103 
cells/well in 96-well plates) were cultured for 6  days to 
compare the proliferation capacities of MSCs from bone 
marrow, adipose tissue, and synovium. Significant differ-
ence was not observed in cell numbers on day 1. However, 
higher proliferation capacity was observed in SM-MSCs, 
which was consistent with other reports [28], followed by 
AD-MSCs and then BM-MSCs from day 2 to day 6 (Fig-
ure  1d, p =  0.001). Under the same induction medium, 
SM-MSCs established the most superior chondrogenic 
potential (Figure  2d, g, and k; Figure  2g: p  =  0.002 vs. 
BM-MSCs, p = 0.001 vs. AD-MSCs; Figure 2k: p = 0.008 
vs. BM-MSCs, p  =  0.001 vs. AD-MSCs). BM-MSCs 
exhibited the most superior osteogenic differentia-
tion potential according to OCN expression (Figure  2f: 
p =  0.002 vs. SM-MSCs, p =  0.001 vs. AD-MSCs) and 
the staining results of ALP and Alizarin red (Figure  2b, 
c, i, j; Figure  2i: p =  0.002 vs. SM-MSCs, p =  0.001 vs. 
AD-MSCs; Figure 2j: p = 0.02 vs. SM-MSCs, p = 0.02 vs. 
AD-MSCs).
All three types of MSCs ubiquitously expressed CD105, 
CD73, and CD90 (CD105: 95.41% in BM-MSCs, 95.08% 
in AD-MSCs, and 91.91% in SM-MSCs; CD73: 97.17% 
in BM-MSCs, 94.67% in AD-MSCs, and 99.73% in SM-
MSCs; CD90: 99.39% in BM-MSCs, 99.85% in AD-MSCs, 
and 98.73% in SM-MSCs) (Figure 3). However, all three 
Figure 1 Morphology and proliferation differences among three types of MSCs. a–c BM-MSCs, AD-MSCs, and SM-MSCs were isolated from the 
bone marrow, adipose tissue, and synovium, respectively. Images show the MSCs at passage 3. Magnification ×10, bar 50 µm. d All three types of 
MSCs were seeded in a 96-well plate at 5 × 103 per well and were cultured for 1, 2, 3, 4, 5, and 6 days. The cell numbers at each day were measured 
using CCK-8 assay. The cells on day 0 were used as control. The data were obtained from three independent experiments, each performed in tripli-
cate. Each bar represents mean ± SD (*p < 0.05, vs. BM-MSCs, at the same time point, ANOVA).
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types of MSCs did not express the hematopoietic marker 
CD45 (Figure 3).
In vitro tenogenic differentiation capacities of MSCs 
from bone marrow, adipose tissue, and synovium 
after Ad‑BMP‑12 infection
The tenogenic differentiation capacities of the three types 
of MSCs in the presence of BMP-12 were compared by 
constructing recombinant adenovirus Ad-BMP-12 as 
we previously reported [26]. Infection efficiency assay 
was used to establish a suitable infection condition. 
Four MOIs (0, 50, 100, and 500) were set up, and MOI 
of 500 was determined as the consistent infection effi-
ciency among the three types of infected MSCs (~100%) 
(Figure  4a). Moreover, increased cell numbers were still 
observed in all MSCs from day 1 to day 3 (Figure 4b).
The effect of Ad-BMP-12 infection on the differen-
tiation capacities of the three types of MSCs was also 
assessed. Tenogenic differentiation was evaluated based 
on the expression of tenocyte-lineage marker genes at 
both mRNA and protein levels. Scleraxis (SCX), a key 
transcription factor during tenogenic differentiation pro-
cess; Tnmd and tenascin-c (Tnc), the tenogenic differen-
tiation markers; and Col I, a major extracellular matrix 
protein were used to assess tenogenic differentiation. 
The expression levels of the aforementioned tenogenic 
genes were assessed at 1, 3, and 7 days after induction by 
real-time reverse transcription polymerase chain reac-
tion (RT–PCR). Upregulated mRNA expression levels 
of all four tenogenic genes were observed in induced 
MSCs but with different patterns. BM-MSCs exhibited 
the highest expression levels of SCX (Figure 5a: 1, 3, and 
7 days; p value is shown in the figure), Tnmd (Figure 5b: 
3 and 7  days; p value is shown in the figure), and Col I 
(Figure 5e: 1, 3, and 7 days; p value is shown in the fig-
ure) among the three MSCs. SM-MSCs showed the high-
est Tnc expression level at 7  days. The basal expression 
levels of SCX, Tnmd, Tnc, and Col I (day 0) were sig-
nificantly different across the three types of MSCs. BM-
MSCs exhibited the highest basal level of SCX (Figure 5a, 
p = 0.001 vs. SM-MSCs, p = 0.001 vs. AD-MSCs), Tnc 
(Figure 5c, p = 0.007 vs. SM-MSCs), and Col I (Figure 5e, 
p  =  0.034 vs. AD-MSCs). By contrast, AD-MSCs had 
the highest basal level of Tnmd (Figure 5b, p = 0.036 vs. 
SM-MSCs).
Upregulated protein expressions of all four tenogenic 
markers were observed in the induced MSCs with time 
duration. The highest expression levels of SCX, Tnmd, 
and Col I were observed in BM-MSCs, whereas the 
highest expression level of Tnc was observed in SM-
MSCs (Figure 5d, p = 0.024 vs. BM-MSCs, p = 0.009 vs. 
AD-MSCs).
All these data suggest the most superior tenogenic 
differentiation capacity of BM-MSCs, followed by SM-
MSCs and then AD-MSCs in vitro.
Comparative analysis of in vivo tendon‑like tissue 
formation in the three types of MSCs
Different capacities of tenogenic differentiation among 
the three types of MSCs are demonstrated by the afore-
mentioned results in  vitro. These differences were also 
examined in vivo. All three types of MSCs were initially 
infected with Ad-BMP-12 for 24 h and then were injected 
subcutaneously into the right axillary region of the nude 
mice. After 3 and 6 weeks, these injected cell masses were 
removed for further analysis. As shown in Figure  6a, 
these cells were aggregated together, and most of them 
presented ellipse-shaped tissues. Significant difference 
between 3- and 6-week samples was not detected at the 
area and weight of the three types of MSCs (Figure  6b, 
c). Tenogenic differentiation was evaluated based on the 
histological findings. No difference was observed in the 
macroscopic morphologies of the cells in all groups; how-
ever, they exhibited different cell arrangements, as shown 
in the hematoxylin/eosin images. Furthermore, regard-
less of the type of MSCs, the organization of the cells 
infected with Ad-BMP-12 was different from that of the 
cells infected with Ad-GFP (Figure  7). The organization 
and arrangement of the control MSCs were poorly organ-
ized, compact, and uniform (Figure  7a1–3, b1–3). By 
(See figure on next page.)
Figure 2 Comparative analysis of the tri-lineage differentiation capacities of the three types of MSCs. a All three types of MSCs were cultured in adi-
pogenic differentiation medium for 14 days and were assessed by oil red O staining (used to identify adipogenic differentiation). Magnification ×10, 
bar 50 µm. b and c All three types of MSCs were cultured in osteogenic differentiation medium for 21 days and were assessed by ALP (alkaline phos-
phatase, a byproduct of osteoblast activity) staining (b) and Alizarin red staining (used to identify calcium deposits) (c). Magnification ×4, bar 50 µm. 
d All three types of MSCs were cultured in chondrogenic differentiation medium for 21 days and were assessed by immunohistochemical staining 
with anti-type II collagen antibody. Magnification ×4, bar 50 µm. e PPAR-γ (adipogenic differentiation marker) was evaluated by real-time RT–PCR at 
0, 3, and 7 days post induction (mean ± SD, n = 3, *p < 0.05, ANOVA). f and g OCN (osteogenic differentiation marker) (f) and Col II (chondrogenic 
differentiation marker) (g) were evaluated by real-time RT–PCR at 0, 7, and 14 days post induction (mean ± SD, n = 3, *p < 0.05, ANOVA). h–j Analy-
sis of oil red O staining (h), ALP staining (i), and alizarin red staining (j). The ratio of positive-stained area to the total area of cells was calculated using 
Image-Pro Plus 6.0 software (mean ± SD, n = 5, *p < 0.05, ANOVA). k Analysis of immunohistochemical staining of collagen type II. Expression levels 
were quantified by mean intensity of the images analyzed using Image-Pro Plus 6.0 software (mean ± SD, n = 5, *p < 0.05, ANOVA).
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contrast, the specimens of the MSCs infected with Ad-
BMP-12 exhibited a special structure. Some of the cells 
were aggregated together and formed numerous small 
cell masses, whereas some parts of the tissues emerged 
in the form of fiber-like matrix, especially in 6-week 
specimens (Figure  7a4–6, b4–6). Immunohistochemical 
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Figure 3 Immunophenotypic profiles of MSCs derived from three different rat tissues. Three types of MSCs at passage 3 (1 × 106) were incubated 
with FITC-conjugated CD105, CD73, CD90, and CD45 antibodies (Abcam, Cambridge, UK) in 1% FBS/PBS for 1 h. Cells were washed three times with 
1% FBS/PBS and then resuspended in 500 μL of PBS. For negative controls, FITC-conjugated nonspecific IgG fractions (Abcam) were substituted for 
the primary antibodies.
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staining for Col I was used to assess matrix produc-
tion after Ad-BMP-12 infection. Rat Achilles tendon 
was employed as positive control; the staining intensity 
was quantified by mean intensity (Figure  8). Compared 
with AD-MSCs, BM-MSCs and SM-MSCs revealed 
more intense staining for Col I in both 3- and 6-week 
specimens (Figure 8a, b, d; 3w: BM-MSC vs. AD-MSCs: 
p = 0.001, SM-MSC vs. AD-MSCs: p = 0.001; 6w: BM-
MSC vs. AD-MSCs: p = 0.017, SM-MSC vs. AD-MSCs: 
p  =  0.031). Difference was not observed between BM-
MSCs and SM-MSCs at both 3 and 6 weeks (Figure 8a, 
b, d).
Discussion
Tendons are poorly vascularized tissues and thus have 
difficulty regenerating. Tendon repair is slow and inef-
ficient after injury. Tenocytes are highly differentiated 
cells and have low cell density. Tenocytes are embed-
ded in 3D extensive extracellular matrix and exhibit low 
proliferation activities. Cell-based regenerative medicine 
appears to have great prospect for clinical applications in 
tendon repair. Screening for an appropriate cell source 
for tendon repair is crucial. The criteria for an ideal cell 
source have been proposed [29]. First, the cells should 
have rapid proliferation capacity because healthy cells 
should be adequate for implantation in  vitro. Second, 
cells should be easy to harvest. The cells should be easily 
isolated without substantial secondary trauma to the har-
vest site. Finally and most importantly, cells should have 
effective repair capacity. A crucial problem is whether 
the harvested cells can easily and effectively repair the 
injured site.
MSCs are potential cell source with considerable clini-
cal applications [30, 31]. MSCs are easy to isolate and 
possess properties, such as self-renewal, low immuno-
genicity, and multilineage differentiation capabilities 
[32–34]. MSCs can be virtually isolated from many tis-
sues, such as bone marrow, adipose, muscle, and syn-
ovium. BM-MSCs have received considerable attention 
from researchers for their remarkable plasticity and sig-
nificant differentiation potential. In recent years, other 
MSC sources have been identified. AD-MSCs isolated 
Figure 4 Influence of recombinant Ad-BMP-12 virus on cell viability. a All three types of MSCs were infected with Ad-BMP-12 at MOIs of 50, 100, 
200, and 500. Untreated MSCs were used as controls. Flow cytometry was used to assess infection efficiency. The data were obtained from three 
independent experiments, each performed in triplicate. Each bar represents mean ± SD (*p < 0.05, vs. control, t test). b All three types of MSCs were 
seeded in a 24-well plate at 1 × 105 per well and infected with Ad-BMP-12 at MOI of 500. Cell numbers were measured using CCK-8 assay on days 
1 and 3. The data were obtained from three independent experiments, each performed in triplicate. Each bar represents mean ± SD (*p < 0.05, vs. 
control, t test). c Images were acquired using a fluorescence microscope to show infection efficiency and cell viability on days 1 and 3. Cells with 
green fluorescence were the infected MSCs. Magnification ×10, bar 50 µm.
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from adipose tissues can be easily isolated by minimally 
invasive techniques. Similar to BM-MSCs, AD-MSCs are 
considered a promising therapeutic cell source because of 
their multilineage differentiation potential [35, 36]. SM-
MSCs have great differentiation potential toward adi-
pogenesis, osteogenesis, chondrogenesis, and myocyte, 
Figure 5 Comparative analysis of the tenogenic differentiation capacities of three types of MSCs. a–c MSCs were cultured with Ad-BMP-12 for 1, 
3, and 7 days. The expression levels of the specific tenogenic genes Scx (a), Tnmd (b), and Tnc (c) were evaluated by real-time RT–PCR at 0, 1, 3, and 
7 days after infection (each bar represents mean ± SD from three independent experiments; *p < 0.05, ANOVA). The BM-MSCs infected with Ad-GFP 
on day 0 were used as control. d Western blot was performed with total proteins from all three types of MSCs at 0, 1, 3, and 7 days after infection to 
detect the levels of Scx, Tnmd, and Tnc. β-Tublin was used as control. e Col I expression was evaluated by real-time RT–PCR at 0, 1, 3, and 7 days after 
induction (each bar represents mean ± SD from three independent experiments; *p < 0.05). The BM-MSCs infected with Ad-GFP on day 0 were 
used as control. f Col I concentration in the cell lysate was quantified at 0, 1, 3, and 7 days post Ad-BMP-12 infection by using a Col I ELISA kit (each 
bar represents mean ± SD from three independent experiments; *p < 0.05, ANOVA).
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suggesting high multipotency [37, 17]. SM-MSCs are 
considered a new source of MSCs for regenerative medi-
cine for the musculoskeletal system [25]. MSCs from 
different tissues differ in proliferation, isolation, and dif-
ferentiation capacities. For example, SM-MSCs and AD-
MSCs are superior in adipogenesis, whereas BM-MSCs, 
SM-MSCs, and periosteum-derived MSCs are superior 
in osteogenesis [17]. Our previous studies elucidated 
the mechanisms of osteogenic differentiation of BM-
MSCs and AD-MSCs and presented differences between 
these mechanisms [18]. Little is still known about the 
differences in tenogenic differentiation capacities. There-
fore, identifying and characterizing the appropriate cell 
source for tendon repair are crucial.
In this study, we compared the proliferation capacities, 
trilineage differentiation capacities, and tenogenic dif-
ferentiation potentials of MSCs. The MSCs were derived 
from rat bone marrow, adipose tissue, and synovium in 
the presence of BMP-12. SM-MSCs exhibited the most 
superior proliferation capacity, followed by AD-MSCs 
and BM-MSCs, which was consistent with the findings 
of previous reports [17, 38]. Furthermore, the tenogenic 
Figure 6 Properties of the implanted Ad-BMP-12 infected cell masses. a MSCs were initially treated with Ad-BMP-12 for 1 day and were then sub-
cutaneously injected into the nude mice for 3 or 6 weeks. The MSCs treated with Ad-GFP were used as control. Images show the morphologies of 
the cell masses after 3 and 6 weeks from injection. b and c Comparison of the three types of MSCs in terms of the area (b) and weight (c) of the cell 
masses. (Each bar represents mean ± SD; *P < 0.05, statistical method: t test: 3w/6w BMP-12 group vs. 3w/6w control group, respectively; ANOVA: 
3w/6w BMP-12 group in BM-MSC vs. 3w/6w BMP-12 group in AD-MSC vs. 3w/6w BMP-12 group in SM-MSC, respectively).
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differentiation capacities among these MSCs were sig-
nificantly different, with BM-MSCs exhibiting the most 
superior tenogenic differentiation capacity, followed by 
SM-MSCs and AD-MSCs, in the presence of BMP-12 
both in vivo and in vitro.
Results showed that BM-MSCs exhibited the most 
superior tenogenic differentiation potential but the most 
inferior proliferation capacity. Painful biopsy procedure 
is another limitation in using BM-MSCs [39, 40]. AD-
MSCs are considered a promising cell source because the 
adipose tissue is ubiquitous and easily obtained, with less 
donor site morbidity [41]. However, in this study, among 
these three MSCs, AD-MSCs exhibited the most infe-
rior tenogenic differentiation capacity. SM-MSCs dem-
onstrated superiority in multipotency and proliferation 
potential compared with the other MSCs [17]. SM-MSCs 
also showed good tenogenic differentiation potential both 
in vivo and in vitro. Unfortunately, SM-MSCs are always 
harvested via arthroscopy, which is an invasive procedure.
In summary, BM-MSCs and SM-MSCs showed the 
most superior tenogenic differentiation and cell prolif-
eration capacities, respectively. AD-MSCs showed the 
most inferior proliferation and tenogenic differentiation 
capacities.
Figure 7 H&E staining of the implanted cell masses. The specimens were fixed and embedded in paraffin. Sections of 5 µm cut through the center 
of the cell masses were stained with hematoxylin/eosin (H&E). Images show the staining at 3 weeks (a) and 6 weeks (b). Magnification ×10, bar 
200 µm.
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Figure 8 Immunohistochemical analysis of implanted MSCs. a and b The specimens were fixed and embedded in paraffin. Sections of 5 µm cut 
through the center of the cell masses were stained with anti-Col I antibody. Images show the staining at 3 weeks (a) and 6 weeks (b). Magnification 
×10, bar 200 µm. c Immunohistochemical staining of Col I of rat Achilles tendon was used as positive control. d Col I expression was quantified 
by mean intensity of the images analyzed using Image-Pro Plus 6.0 software. Achilles tendon was used as positive control (each bar represents 
mean ± SD, n = 5; *p < 0.05, ANOVA).
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The results of this study provide useful information on 
selecting the optimum MSCs to improve tendon repair. 
Further study on MSCs of other species, especially 
human MSCs, should be performed and verified.
Conclusion
BM-MSCs exhibited the most superior tenogenic dif-
ferentiation capacity, followed by SM-MSCs. By con-
trast, AD-MSCs demonstrated the most inferior capacity 
among the three types of MSCs in the presence of BMP-
12 both in  vivo and in  vitro. This study provides useful 
information on selecting the optimum MSCs to improve 
tendon repair.
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